ARIZ One of “Eight Nanotechnology Companies to Watch Out for”

1 min read

Today, as the field of precision medicine thrives, ARIZ Precision Medicine, a biotech company based in California in the U.S., aims to incorporate nanotechnology for the targeted delivery of cancer drugs.

The company’s product is composed of a nanoparticle, which is customized based on the kind of cancer it is attacking, and has small interfering RNA (siRNA) that kill proteins that drive cancer without harming the neighboring healthy cells, cancer cell targeting peptides, as well as the chemotherapy drug – which is encapsulated within the nanoparticle. The nanoparticle is PEGylated, a process by which the polymer polyethylene glycol (PEG) is added to protect the drug.

The company has eight indications in its pipeline, which target the PRDM class of proteins responsible for enabling the proliferation of cancer cells.

Since its inception in 2015, the company has raised a total of $2.7 million over three financing rounds. The latest funding round took place in 2022. Recently, it was awarded access to lab space at California-based Bakar Labs to develop its cancer therapies, all of which are being pre-clinically studied.

NIH Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome

ResVita Bio is pioneering continuous protein therapy, delivered through a genetically engineered probiotic platform that temporarily colonizes the skin and continuously releases therapeutic proteins, such as LEKTI, to inhibit protease activity. This continuous delivery method ensures high levels of the therapeutic agent at the site of damage, restoring the integrity of the skin barrier. This represents a significant shift from traditional therapies, which may not provide sustained treatment at the site of the disease.

Read post

The AI Effect: How a Hot Computing Tool Is Tying ‘Bio’ and ‘Tech’ Closer Than Ever

“In protein design, until the last couple of years, successes were rare,” said Fraser, a professor of bioengineering and therapeutic sciences in UCSF's School of Pharmacy. “(AI has) just been a sea change. Stuff works now.” Those successes are elevating a new generation of AI-focused drug-development companies in the Bay Area, including Profluent Bio, a 20-person Berkeley startup founded by the leaders of the Salesforce project. In the wake created by ChatGPT and a wealth of biological data, those companies may be key to AI’s evolving ability to fix human ills.

Read post

Startup Launches With ‘RNA Sensor’ Technology From Stanford and MIT To Better Control mRNA Therapies

“We want to turn off an RNA transcript and prevent it from being expressed by default,” CSO Eerik Kaseniit, a former graduate student who worked on the technology in Gao’s lab, told Endpoints News in an interview. Radar’s scientists do that by adding a stop codon — three genetic letters that are the molecular equivalent of a red light — in front of the mRNA therapy, which prevents cells from reading the message.

Read post

ARIZ One of “Eight Nanotechnology Companies to Watch Out for”

News Updates

Learn More

Berkeley startup wins government award to develop radiation and lead poisoning treatment

HOPO Therapeutics wins up to $226M BARDA contract for heavy metal poisoning research

NIH Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome

Minutia Receives Phase I SBIR Grant from National Institutes of Health

The AI Effect: How a Hot Computing Tool Is Tying ‘Bio’ and ‘Tech’ Closer Than Ever

Startup Launches With ‘RNA Sensor’ Technology From Stanford and MIT To Better Control mRNA Therapies